Battelle breakthrough could help autistic children receive treatment sooner

Battelle scientists have identified a low-cost urine test that potentially predicts the presence of autism spectrum disorder (ASD) at an early age.

ASD, which is defined by behavioral characteristics, has been difficult for physicians to diagnose at an early age before these behaviors become more apparent (usually about two years of age or older). Recent research indicates that ASD affects 1 in 88 children in the U.S.

The Battelle team of Drs. Nicholas Heyer and Diana Echeverria joined with Professor James Woods at the University of Washington’s School of Public Health to evaluate the levels of porphyrins in the urine of children with ASD to determine if certain levels of specific porphyrins could predict ASD.

Identifying this link may have important clinical implications for diagnosis and treatment. The ability to detect porphyrins, a group of naturally occurring organic compounds, in a simple urine test allows for a rapid, low-cost and widely used screening test for identifying young children at a high risk for ASD.

“This is significant because it means children may be diagnosed with ASD at an earlier age and can thus receive treatment sooner. Early treatment can lead to a better quality of life for children with ASD,” Heyer said.

The findings were published in this month’s edition of Autism Research, and coincide with Autism Awareness Month.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

Enable Injections featured in article on safer, simpler, smarter devices for drug delivery | Drug Development & Delivery, September 15, 2014

BioOhio takes 2014 Annual Conference “on the road” in series of three regional events | Business Wire, September 15, 2014

ABC’s of IND’s – ChanTest to Host Session at the Safety Pharmacology Society (SPS) Annual Meeting | PR Web, September 15, 2014

Nationwide Children’s Hospital discusses Enterovirus D68 | Nationwide Children's Hospital, September 12, 2014

Akebia Therapeutics (NASDAQ: AKBA) to ring the NASDAQ Stock Market Opening Bell | NASDAQ, September 11, 2014

$1M grant to Cincinnati Children’s intended to improve human growth and development around the world | CCHMC, September 10, 2014

Airway Therapeutics gets money to advance treatment for smallest and sickest babies | WCPO9 Cincinnati, September 10, 2014

Airway Therapeutics raises $4.6M in Series A financing | CincyTech, September 10, 2014

Airway Therapeutics announces $4.6M funding round | Cincinnati.com, September 10, 2014

Alkermes anti-addiction drug Vivitrol helping inmates at Barnstable County Correctional Facility (MA) | Boston Business Journal, September 8, 2014

Nationwide Children’s Hospital now home to the world’s largest Ronald McDonald House | Columbus Dispatch, September 8, 2014

Envision Pharmaceutical completes its acquisition of MedTrak Services (Kansas) | Herald Online, September 8, 2014

Ohio Capital Fund key player in state startup scene | Cincinnati.com, September 6, 2014

Navidea enters Lymphoseek development and commercialization agreement with Hainan Sinotau Pharmaceutical Co., Ltd. subsidiary in China | Navidea Pharmaceuticals, September 4, 2014

Ricerca Biosciences in discussions to be acquired | OutsourcingPharma.com, September 3, 2014

Meridian Bioscience signs agreement with Premier to offer its hospitals molecular diagnostic tests and instruments | Business Wire, September 3, 2014

Cleveland Functional Electrical Stimulation Center taking toy donations at Expo to help disabled children | WKYC3 NBC, September 2, 2014

Aerpio Therapeutics announces publication of preclinical data on AKB-9778 for common eye diseases | Business Wire, September 2, 2014

Cleveland, Neuros Medical, featured in US News article on urban revitalization | US News, September 2, 2014

Thanks to smart moves, STERIS stock is on the rise | Crain's Cleveland Business, August 31, 2014